|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | A61K 31/495 | (2006.01) |
| A61P 15/10 | (2006.01) |
| (11) | Number of the document | 0839040 |
| (13) | Kind of document | T |
| (96) | European patent application number | 96923985.4 |
| Date of filing the European patent application | 1996-07-11 | |
| (97) | Date of publication of the European application | 1998-05-06 |
| (45) | Date of publication and mention of the grant of the patent | 2006-05-31 |
| (46) | Date of publication of the claims translation | 2006-07-25 |
| (86) | Number | PCT/EP1996/003024 |
| Date | 1996-07-11 |
| (87) | Number | WO 1997/003675 |
| Date | 1997-02-06 |
| (30) | Number | Date | Country code |
| 9514464 | 1995-07-14 | GB |
| (72) |
DAUGAN, Alain Claude-Marie, Lab.Glaxo Wellcome S.A, FR
|
| (73) |
ICOS Corporation,
22021 20th Avenue S.E., Bothell WA 98201,
US
|
| (74) |
Tatjana STERLINA,
UAB "Intels", Naugarduko g. 32/2, LT-03225 Vilnius,
LT
|
| (54) | CGMF-fosfodiesterazės inhibitorių panaudojimas impotencijos gydymui |
| USE OF CGMP-PHOSPHODIESTERASE INHIBITORS TO TREAT IMPOTENCE |
| Payment date | Validity (years) | Amount | |
| 2015-06-24 | 20 | 347.00 EUR |